MammoCAT Advanced Full Field Digital Mammography System

MammoCAT 先进的全视野数字乳腺 X 线摄影系统

• 批准号: 10481694
• 负责人: Shabbir Bakir Bambot
• 金额: $ 102.34万
• 依托单位: FISCHER IMAGING, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10481694
• 关键词: 3D Print; Address; Appearance; Architecture; Attention; Back; Biopsy; Bone Tissue; Breast; Breast Cancer Detection; Cancer Etiology; Cessation of life; Chest wall structure; Clinical; Computer software; Custom; Development; Devices; Diagnosis; Digital Breast Tomosynthesis; Digital Mammography; Disease; Dose; Enhancement Technology; Evaluation; Filtration; Future; Image; Laboratories; Low Dose Radiation; Malignant Neoplasms; Mammography; Measurement; Mechanics; Methods; Pain; Patients; Performance; Phase; Population; Privatization; Probability; Procedures; Production; Quality Control; Radiation Dose Unit; Radiation Scattering; Reading; Recommendation; Resolution; Rest; Roentgen Rays; Safety; Scanning; Services; Shapes; System; Technology; Testing; Time; Tube; United States; Validation; Woman; Work; attenuation; base; calcification; commercialization; compliance behavior; contrast imaging; cost; cost effective; design; improved; lifetime risk; malignant breast neoplasm; mortality; novel; prototype; radiation risk; radiological imaging; radiologist; research clinical testing; screening; soft tissue; tomosynthesis; tool; tumor; unnecessary treatment; usability; young woman

Project Summary Breast cancer remains a leading cause of cancer related death among women in the United States. Mammography, the only cost effective method approved for population screening of breast cancer, fails to find cancer in many women and causes too many unnecessary call backs on the rest. Fischer Imaging has developed proprietary “slot scanning” technology that significantly improves contrast and image resolution of today’s mammography and lowers the radiation dose. Our technology also removes the need for painful breast compression. These essential enhancements will improve clinical performance by finding missed cancers and reducing unnecessary treatment while increasing patient compliance with mammography recommendations. This proposal describes the development and feasibility bench testing of MammoCAT™ DM, our first product, which will provide superior two view mammography. This product is regulated as a Class II, 510k device and current procedure reimbursement by CMS and private payors allows a facility with an average patient volume to pay off the device in about a year. A key feature of MammoCAT DM will be upgradeability to MammoCAT DBT, our second product, which will allow image capture over multiple angles to give it digital breast tomosynthesis capability.

项目总结